LONG-TERM DEBT (Tables)

12 Months Ended

Aug. 01, 2020

The Company’s long-term debt consisted of the following:



(in thousands)	Average Interest Rate at August 1, 2020	Fiscal Maturity Year	August 1, 2020			August 3, 2019
Term Loan Facility	4.41%	2026	$	1,773,000		$	1,864,900
ABL Credit Facility	1.58%	2024	756,712			1,080,000
Other secured loans	5.19%	2024-2025	49,268			57,649
Debt issuance costs, net			(45,846		)	(54,891		)
Original issue discount on debt			(35,508		)	(41,175		)
Long-term debt, including current portion			2,497,626			2,906,483
Less: current portion of long-term debt			(70,632		)	(87,433		)
Long-term debt			$	2,426,994		$	2,819,050

Schedule of Maturities of Long-term Debt

Future maturities of long-term debt, excluding debt issuance costs and original issue and purchase accounting discounts on debt, as of August 1, 2020, consist of the following:



Fiscal Year	(In thousands)
2021	$	84,773
2022	13,465
2023	14,196
2024	764,669
2025	18,877
2026 and thereafter	1,683,000
	$	2,578,980

Schedule of Line of Credit Facilities

The assets included in the Consolidated Balance Sheets securing the outstanding obligations under the ABL Credit Facility on a first-priority basis, and the unused credit and fees under the ABL Credit Facility, were as follows:



Assets securing the ABL Credit Facility (in thousands)⁽¹⁾:	August 1, 2020
Certain inventory assets included in Inventories and Current assets of discontinued operations	$	2,270,892
Certain receivables included in Accounts receivable, net and Current assets of discontinued operations	$	1,077,682


(1)	The ABL Credit Facility is also secured by all of the Company’s pharmacy scripts, which are included in Intangible assets, net in the Consolidated Balance Sheets as of August 1, 2020.



Unused available credit and fees under the ABL Credit Facility (in thousands, except percentages):	August 1, 2020
Outstanding letters of credit	$	95,906
Letter of credit fees	1.375		%
Unused available credit	$	1,234,758
Unused facility fees	0.25		%